Predictive Oncology

AUGUST 8, 2024

A recent white paper released by Predictive Oncology’s highlights the challenge of late-stage clinical trial failures and the company’s ability to better navigate those obstacles and increase the probability of technical success which is a key metric in target selection, clinical trial design and pipeline replenishment.

Drug Development 52

Drug Development Clinical Trials Animal Testing Drugs 52

Predictive Oncology

AUGUST 15, 2024

White paper validates highly reproducible drug response data. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.

Drugs 52

Drugs Drug Development 52

Predictive Oncology

AUGUST 15, 2024

White paper validates highly reproducible drug response data. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.

Drugs 52

Drugs Drug Development 52

Fierce BioTech

JUNE 24, 2024

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. Read this white paper to learn more. Read this white paper to learn more.

Drugs 52

Drugs Drug Development Production Research 52

PPD

OCTOBER 21, 2024

Meeting the never-ending challenges of drug development in this active environment — including pressure to identify drug prospects earlier and hire more conservatively — frequently leads biotech companies to outsource some portion of clinical development functions.

International 87

International Clinical Development Clinical Trials Clinical Research 87

Conversations in Drug Development Trends

MARCH 1, 2024

To help determine if a master protocol could be a good fit for your study, check out this white paper for a more comprehensive overview of the appropriateness of master protocols in different contexts. Here are some relevant factors below: What Are the Advantages of a Master Protocol? Contact us.

Trials 78

Trials Disease Drug Development Clinical Trials 78

Fierce BioTech

JULY 28, 2023

jsabatino Fri, 07/28/2023 - 11:29 In this white paper, we look at the past, present and future of antibodies as therapies, explaining how the modality became a key pillar of the biopharma industry—and looking forward to the methods and technologies that could unleash its full potential in the years to come. Download here!

Therapies 52

Therapies Drug Development Research Drugs 52

Conversations in Drug Development Trends

APRIL 4, 2024

Global Impact of ICH M10 Validation Guidelines Harmonization of bioanalytical validation methods is crucial in a world where pharmaceuticals are developed and approved across different regions. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

Drug Channels

MAY 20, 2021

Karen examines trends in drug development, pricing, and healthcare. To learn more, download Six trends and tactics to thrive in the new healthcare economy , a free white paper from Wolters Kluwer. She also serves as co-chair of Maintenance and Control at the NCPDP. Read on for Karen’s insights.

Drug Development 52

Drug Development Drugs 52

Conversations in Drug Development Trends

FEBRUARY 21, 2024

We recently published a white paper discussing the value of proactive AME studies, best practices, and lessons we’ve learned over the years to help optimize your study. At Worldwide, our early phase team has conducted these studies for over 20 years, gaining invaluable experience and insights into best practices for an AME study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

Alta Sciences

SEPTEMBER 5, 2024

New Findings on the Sinclair Nanopig™ in Safety Studies blussier Thu, 09/05/2024 - 18:00 HTML Recent Scientific Data Challenges the Status Quo Our most recent white paper presents detailed genomic, proteomic, and functional data on the Sinclair Nanopig™’s metabolism and immune systems. Read it now! ​​​​​​ WHITE PAPER Questions?

Drug Development 40

Drug Development Drugs Research 40

The Pharma Data

JANUARY 18, 2021

There is no way to eliminate the risk of failure. However, there are ways to reduce these risks. Learn more in this whitepaper from Recipharm. Source link.

Drug Development 52

Drug Development Drugs 52

PPD

AUGUST 28, 2024

For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. Drug developers must consider ways to remove these barriers to enhance their ability to recruit and retain trial participants.

Trials 69

Trials Clinical Trials Drug Development Therapies 69

Conversations in Drug Development Trends

NOVEMBER 21, 2023

In contrast, as a nonprofit organization, Every Cure can prioritize assets with the greatest opportunity for impact, filling the treatment gap that many traditional drug developers are not positioned to fill. To learn more about the Every Cure and Worldwide partnership, listen to a recent podcast episode between Dr.

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

PPD

OCTOBER 2, 2024

A recent white paper from the PPD™ clinical research business of Thermo Fisher Scientific details how these functions have evolved over the years, moving from capabilities that were previously built up and maintained in-house, to the multiple outsourcing models available today.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

PerkinElmer

FEBRUARY 18, 2021

Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings. It is an ongoing debate.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

Conversations in Drug Development Trends

MARCH 20, 2024

In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. As the study of how an individual’s genes affect their response to drugs, pharmacogenomics is a critical factor in developing effective and safe drugs and dosages in clinical trials.

Clinical Trials 52

Clinical Trials Trials Treatment Drug Development 52

Conversations in Drug Development Trends

AUGUST 14, 2024

However, at Worldwide, we have a proven track record of successfully utilizing biomarkers in oncology development. Check out our white paper to learn more about our services, or contact our team to find out how we can help support your oncology drug development program.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Conversations in Drug Development Trends

MARCH 7, 2024

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

Conversations in Drug Development Trends

DECEMBER 20, 2023

You can learn more about biomarkers and how to use them in oncology studies in this white paper.

Clinical Trials 83

Clinical Trials Trials Pharmacokinetics FDA 83

Perficient: Drug Development

SEPTEMBER 17, 2024

AI content generator: Generative AI is seamlessly integrated into existing content creation workflows to assist marketers in creating various types of content, from text like headlines and white papers to images. Customers also have the flexibility to use their preferred AI models or providers.

Marketing 109

Marketing Production Government 109

H1 Blog

AUGUST 10, 2023

To learn more about how Medical Affairs teams can leverage AI for smarter drug development, download our Custom White Paper with First Word Pharma: How AI Can Save Medical Affairs from Drowning in Data. Look for more content in our upcoming AI Content Hub.

Drug Development 52

Drug Development Science Production Drugs 52

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. A number of strategies can be adopted to put the needs of the child at the center of the study.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

The Pharma Data

OCTOBER 16, 2020

We are in the process of finalizing arrangements with a global leader in drug development to assist in our development activities as we work toward a potential IND filing targeted in 2021.”. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

PPD

DECEMBER 19, 2023

Ready to fuel more efficient drug development? Read our white paper to learn the keys to successfully implementing functional service partnerships. LEARN MORE The post Dedicated Roles Keep FSP Projects on Schedule appeared first on PPD Inc.

International 52

International Research Drug Development Pharmaceuticals 52

Conversations in Drug Development Trends

MARCH 1, 2023

See how to unlock the full power of your CRO partner in our white paper, Optimal Outcomes in Clinical Research and Product Development. The post Transformational Relationships: How a Consultative Approach from a CRO Adds Value to Your Development Program appeared first on Worldwide Clinical Trials.

Clinical Research 52

Clinical Research Clinical Trials Science Trials 52

PPD

JUNE 17, 2024

Often, however, a hybrid use case will fit into one of these general categories: 1) An existing FSO arrangement needs additional expertise or resources to support a specific study function, requiring the developer to scale or augment that FSO arrangement with FSP services.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

Conversations in Drug Development Trends

JULY 29, 2024

A patient-centric approach that emphasizes empathy, precision, and innovation is essential to advance the standard of care and encourage patients to follow intervention treatments more successfully.

Clinical Research 52

Clinical Research Research Clinical Trials Treatment 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The workshop is also discussed in Cell & Gene here and here.

Therapies 59

Therapies Engineering Production FDA 59

The Pharma Data

DECEMBER 28, 2020

Dr. Russell has managed all aspects of the drug development and regulatory approval processes for oncology and non-oncology drug candidates. Mr. Weild authored and co-authored a number of definitive white papers that were key catalysts for new legislation and regulatory reforms, including the JOBS Act.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

PPD

JULY 9, 2024

Drug developers need to staff RA teams that can handle regular lifecycle maintenance ebbs and flows across lifecycle maintenance tasks, and plan for a workload that sometimes requires senior-level expertise, while at other times is much more suited to support staff. However, completing this work is only half the challenge.

Compliance 52

Compliance Production Clinical Research Marketing 52

The Pharma Data

SEPTEMBER 9, 2020

Receive expert-led insight from Dr. Heiner Oberkampf, Head of Data Governance at OSTHUS and learn how to: Digitally transform a drug development strategy. Develop a fully automated environment to significantly boost research efforts.

Production 52

Production Laboratories Compliance Government 52

Conversations in Drug Development Trends

MARCH 12, 2024

For a more in-depth look at biomarkers, check out our white paper. The IO biomarker field is rapidly evolving—check out this white paper for the latest details regarding IO biomarkers. Below, we discuss some validated circulating oncology biomarkers, their implementation, and key operational considerations.

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

EG Life Sciences

FEBRUARY 15, 2023

The year 2022 reflected a transformative path for the drug development industry. Every year, the FDA’s Center for Drug Evaluation and Research (CDER) clarifies to drug developers required study design elements, as well as other data needed on the drug application to support a full and comprehensive assessment.

Drug Development 52

Drug Development FDA Approval Drugs Virus 52

PPD

NOVEMBER 25, 2024

However, a significant challenge drug developers face is that of non-enrolling sites. As the clinical trials landscape continues to evolve toward increased complexity, greater efficiency and accelerated development timelines, the ability to manage and optimize site performance has become even more critical.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

Alta Sciences

OCTOBER 28, 2024

White Paper: Whole Genome Sequencing, Proteomics, and Function Characterization of the Sinclair Nanopig™ Discover how the Sinclair Nanopig™ is transforming nonclinical safety assessments. Read the white paper. Issue 41 of The Altascientist focuses on bioanalytical testing for immunomodulatory drugs. Watch it now.

Science 52

Science Clinical Trials Trials FDA 52

LifeSciVC

MARCH 12, 2025

This circumventing the wheel requires navigating around the roadblocks that hampered earlier drug development efforts to bring new treatment options forward for patients. Numerous white papers, scientific publications, presentations, and industry news articles focus on ADCs. ADCs are here to stay.

FDA Approval 52

FDA Approval Disease FDA Science 52